Company intelligence / Profile preview
Aeterna Zentaris
Toronto, Ontario, Canada
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing and commercializing novel treatments and diagnostic tests. Its flagship product, Macrilen (macimorelin), is the first and only FDA and EMA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency (AGHD). In 2024, the company completed a merger of equals with Ceapro Inc., integrating the PGX technology platform and a portfolio of bioactive ingredients derived from natural sources.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Small moleculePeptidesNatural products
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Aeterna Zentaris.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aeterna Zentaris.